Botanix Pharmaceuticals Limited (ASX:BOT) today announced that a peer-reviewed article appearing in The Journal of the American Academy of Dermatology (JAAD) has reaffirmed the favourable safety and benefit-risk profile of its key product, Sofdra®. Botanix Pharmaceuticals, a commercial dermatology company, has received FDA approval for Sofdra, a topical gel used to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children aged nine and older. This significant publication reinforces confidence in Sofdra’s performance based on extensive US postmarketing safety data.
The brief report, published online in JAAD, analysed spontaneously reported adverse events for Sofdra® in the United States from June 18, 2024, to January 31, 2026. During this postmarketing period, 20,667 Sofdra® prescriptions were filled, with a total of 194 reports involving 431 adverse events received from US healthcare providers and consumers. Of these, 249 events were identified as drug-related. The authors concluded that no unexpected adverse events were observed, with the types of events generally consistent with sofpironium’s known safety profile and the US prescribing information.
The analysis further noted 16 serious drug-related adverse event reports, encompassing 29 events, which represented a low 0.08% of the postmarketing population. Notably, no drug-related serious adverse events were observed during the pivotal phase 3 trials. Dr Howie McKibbon, Botanix Chief Executive Officer, welcomed the analysis, stating, “Transparent reporting of real-world safety data matters to prescribers and patients. We are encouraged that the authors found adverse event types to be generally consistent with the known safety profile of Sofdra®.” This publication provides further assurance regarding Sofdra® as a treatment option.
